European Society of Pathology September 12-16, 2026 Stockholm, Sweden www.esp-pathology.org
Nilo Therapeutics has launched with $101 million in Series A financing to develop therapies that target the brain’s control of immune responses, marking a significant departure from conventional approaches to autoimmune and inflammatory disease treatment. The funding round, led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and […]
EUROIMMUN has introduced two ELISAs for the detection of IgM and IgG antibodies against Oropouche virus. Oropouche virus is the causative agent of Oropouche fever, an emerging disease which manifests with dengue-like symptoms such as sudden onset of high fever, myalgia, rash, joint pain and vomiting. The virus circulates in Central and South America and […]
respons®940 is an automated random access clinical chemistry analyzer and offers a constant throughput of minimum 400 tests/h, independently whether a mono- or two component reagent is used. Including the optionally available ISE module with additional 240 test/h the total throughout increases to 640 tests/h.
Biotech Fluidics has published a practical review paper that demonstrates how its MarvelX™ and MarvelXACT™ high pressure fluidic connections enable users to achieve reliable, repeatable, and consistent UHPLC performance. In this paper, fluidic experts explore the connection challenges facing users of modern UHPLC instruments.
Beckman Coulter Life Sciences has introduced a new Light Array Module (LAM) for the BioLector XT Microbioreactor which is set to advance research with a wide range of phototrophic organisms.
FUJIFILM Irvine Scientific, a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, has more than doubled their R&D facility’s footprint with the recent completion of its Armstrong Cell Culture Center of Excellence.
German independent research institute BioMed X has started a new research project ‘Advanced Biomarker Detection for Pharma-cological Monitoring in the Brain’ (BDB) in collaboration with Boehringer Ingelheim. The objective of the research group ‘BDB’ is to develop a continuous monitoring biosensor for direct detection of small molecule biomarkers in rodent brain tissue to support the […]
CytoSMART Technologies has launched their new brightfield live-cell imaging system – the CytoSMART Lux3 BR. The small brightfield microscope is equipped with a high-quality 6.4 MP CMOS camera.
Like other CytoSMART microscopes, this new live-cell imager is designed to work inside a standard cell culture incubator without disturbing temperature, airflow, and optimum culture conditions for the cells. This allows researchers to perform long-term live-cell imaging experiments, ensuring optimal cell growth and health.
Very detailed brightfield images can be captured using the new device. With 2072 pixel resolution in both x- and y-axes, combined with 1.45 mm field of view, the microscope provides a resolution of 0.7 µm/pixel. Even at the commonly required image resolution of 300 dpi for printed publications, these images can fill the entire page without compromising image quality.
Jan-Willem van Bree, CTO at CytoSMART Technologies, commented: “We are very excited to expand our label-free microscopy solutions for live-cell studies. For cell biologists who want to incorporate live-cell imaging into their workflow, the resolution of live-cell imaging microscopes may be too low for accurately quantifying complex read-outs, such as cell tracking or differentiation processes. This causes inaccurate and variable results that compromise the research output. Unlike the high-end microscopes with incubation box, the Lux3 BR ensures that cultures are not exposed to temperature, humidity, or CO2 fluctuations that can stress the cells, as the device easily fits in every CO2-incubator. It is a powerful addition to each research lab.”
The CytoSMART Lux3 BR setup can be easily expanded to two or even four devices that can be operated and controlled individually via a single laptop. Since both Lux3 BR Duo Kit and Multi Lux3 BR devices can be placed directly next to each other in the same incubator, it allows for systematic comparison of control and treated samples, as all monitored cell cultures are maintained in an identical culture environment.
The main features and benefits of the CytoSMART Lux3 BR include:
For more information, visit: CytoSMART-Lux3-BR
ZTA Biotech, a Budapest-based biotech startup has announced the breakthrough development of a COVID-19 antibody (IgG) test using the ELISA protocol. This new detection method represents a great step forward in determining if patients have had COVID-19 and if they might still have immunity to the disease. Early results have proven 100% in specificity after testing 280 samples, and 100% sensitivity by testing 260 samples of recovered and symptomatic patients.
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
